BioAtla (BCAB) FCF Margin (2020 - 2026)

BioAtla's (BCAB) quarterly FCF Margin came in at 6.45% in Q2 2026, up 98.37% quarter-over-quarter from 395.75% in Q4 2025.

Analysis

BioAtla (BCAB) FCF Margin (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported FCF Margin for 5 consecutive years, with 6.45% the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, FCF Margin changed N/A year-over-year to 6.45%; the trailing twelve-month figure through Jun 2026 stood at 276.26% (up 19940.0% YoY), and the FY2025 full-year result was 2410.2%, down 175624.0% from the prior year.
FCF Margin improved to 6.45% in Q2 2026 per BCAB's latest filing, from 395.75% in the prior quarter.
Across five years, FCF Margin topped out at 6.45% in Q2 2026 and bottomed at 395.75% in Q4 2025.
Historically, FCF Margin has averaged 149.62% across 3 years, with a median of 46.65% in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	34.70%
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	44.00%
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	30.39%
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	13.35%
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	-
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	-388.28%
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	22.62%
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	14.91%
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	-22.35%
10	BioAtla	2.33 Mn	2.33 Mn	-	-6.45%

Historic Data

Download Data